Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals announced that its CEO, Dr. Howie McKibbon, will present at the Canaccord Drug and Device Healthcare Conference in Noosa. The presentation aims to engage institutional investors and is part of a broader investor roadshow hosted by Canaccord Genuity. This event is significant as it provides Botanix an opportunity to showcase its FDA-approved product, Sofdra®, and potentially strengthen its market position and investor relations.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, US. The company has received FDA approval for its lead product, Sofdra®, which is the first and only new chemical entity approved to treat primary axillary hyperhidrosis, offering a novel solution for patients with this condition.
Average Trading Volume: 8,802,218
Technical Sentiment Signal: Sell
Current Market Cap: A$285.7M
See more data about BOT stock on TipRanks’ Stock Analysis page.